|
⚲
|
| Keyboard |
| Athyrium Capital Management LP
✚
|
|
|---|---|
| CRD # | 161528 |
| SEC # | 801-73737 |
| CIK # | 0001728001 |
| AUM | 2,510.8 M (2026-03-23) |
| Employees | 20 (55% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-402-6925 |
| Address | 505 Fifth Avenue New York, NY 10017-4920 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/23/2026) [Brochure] |
|---|
Item 5. Fees and Compensation The Adviser usually charges each Client an investment management fee based on the value of the Client’s assets under management. Management fees are negotiated on an account-by-account basis and generally relate to the services provided by the Adviser. Management fees are generally in the range of 1 percent to 1.5 percent per annum. Certain Clients that are part of a larger fund structure, such as a dedicated co- investment vehicle, may not pay any management fee. The Funds structured with capital commitments and finite investment periods are generally charged a management fee payable quarterly in advance which is based upon committed capital or invested capital, or both, during the investment period. After the end of the investment period, the management fee is generally the lower of remaining invested capital or remaining fair value of such Fund’s investments. Where applicable, fees and expenses charged to the Clients are generally deducted from the assets of the Client, subject to the specific terms in each Client’s applicable governing documents and/or Advisory Agreements. In addition to paying investment management fees and, if applicable, Carried Interest or other compensation, subject to the applicable provisions of each Client’s offering memorandum and/or governing documents, certain Clients are also subject to certain other expenses, including, but not limited to: (i) tax compliance, financial advisers, consulting, and other out-of-pocket fees, costs, disbursements, and expenses of professional advisers, such as legal counsel (including unreimbursed fees, costs and expenses in connection with acquiring investments or proposed investments on behalf of the Client, hedging investments, and holding, monitoring, distributing and disposing of those investments and hedges), administrators, custodians, depositaries or nominees, consultants, valuation experts, expert networks, loan administrators, loan servicers and agents, appraisers and prime brokers; (ii) audit and Client accounting and Client administration expenses (including maintaining the books and records of a Client, including any related internal costs that the Adviser may incur to produce any such books and records or external costs for a third-party administrator to maintain and oversee a Client’s books and records), certification fees and any other expenses associated with the preparation of the Client’s financial statements, tax returns and Schedules K-1 (or equivalent information); (iii) domestic and foreign taxes, fees or other governmental charges levied against the Client; (iv) expenses associated with the preparation, printing and distribution of reports to the investors in the Client and costs and expenses associated with Client and advisory committee meetings (including, without limitation, keynote speaker fees) and costs associated with educational conferences sponsored by the Adviser for the benefit of Portfolio Company management; (v) investment banking and similar finder’s, consulting and professional fees associated with the sourcing, investigating, diligence, acquisition, holding, monitoring, distributing and disposition of the Client’s investments or proposed investments (as applicable), including unconsummated investments; (vi) broken deal expenses (including expenses that would have been borne by co-investment vehicles if the investment had been consummated) and extraordinary expenses (such as litigation, if any); (vii) syndication costs and expenses; (viii) all other out-of-pocket fees, costs and expenses relating to the sourcing, diligence, acquisition, holding, monitoring and disposition of potential investments and the actual or proposed acquisition, holding, monitoring or disposition of securities and other financial instruments (including, without limitation, subscription costs for market or industry research, subscription costs for related software, banking fees, brokerage and underwriting commissions, transfer taxes, finder’s and consultant’s commissions, fees and expenses, custody costs, hedging costs (including the expenses, fees and costs related to borrowing securities) and the costs of meals, travel and lodging (including, as permitted by the Adviser’s policies and procedures, first class travel, and cars and meals outside normal business hours), including for industry conferences and extraordinary expenses (such as costs and expenses of any threatened or actual litigation); (ix) fees for industry conferences; (x) costs and expenses of forming and maintaining special purpose vehicles, intermediate investment vehicles (including domiciliation costs); (xi) insurance, indemnity, exculpation or litigation (threatened or actual) expenses relating to or arising from the Client or its investments (whether or not consummated) and any judgments or settlements paid in connection therewith; (xii) syndication costs and expenses and placement fees; (xiii) the costs of forming any alternative investment vehicle; (xiv) all other costs or liabilities incurred in connection with the administration, operation and activities of the Client (including, but not limited to, (a) any registration, regulatory, or licensing fees incurred in connection with operating a Client, and other regulatory matters, including costs and expenses of periodic regulatory reporting and other filings, (b) expenses associated with engaging sub-advisers, (c) expenses associated with the use of paying agents and local representatives as may be necessary or appropriate to comply with applicable local law, (d) expenses incurred in connection with the winding up or dissolution of a Client and its related vehicles (and the distribution, realization or disposal of the Client’s investments and other assets pursuant thereto), (e) costs and expenses incurred in relation to obtaining waivers, consents or approvals of the investors in the Client, and costs and expenses ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/23/2026) [Brochure] |
|---|
Item 7. Types of Clients The Adviser’s Clients generally consist of private funds, but may also include individuals, banks and thrift institutions, pension and profit-sharing plans, trusts, estates, charitable organizations, endowments, corporations, insurance companies and other business entities. Set forth below are the minimum account requirements for the Adviser’s accounts: Pooled Investment Vehicles Investors that are United States persons must be “accredited investors” under Regulation D of the Securities Act of 1933, as amended (the “1933 Act”), “qualified purchasers” under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and “qualified clients” eligible to be charged performance fees under the Investment Advisers Act of 1940, as amended (the “Advisers Act”). The minimum investment required by an investor varies depending on the Fund and in each case is subject to waiver by the Adviser. Investors should review the offering memorandum and the applicable governing documents for each relevant private fund for further information with respect to minimum requirements for investment. Specific Vehicles The Adviser may create specific tailored vehicles on a case-by-case basis, such as the Specific Vehicles. These customized vehicles are designed to meet the specific risk and return goals, liquidity restraints, factor sensitivity targets and other requirements of the applicable investors. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Innovative Acquisitions Corp | 3.2 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Athyrium Opportunities Fund IV LP | [2021-08-24] | 185.0 M | 216.5 M |
| Filed 2021-12-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund IV Master Non-US LP | [2021-08-24] | 78.2 M | 1,270.3 M |
| Filed 2021-12-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Athyrium Opportunities IV Co-Invest A LP | 2021-08-24 | 105.3 M | |
| HF | Athyrium Healthcare Strategic Income & Growth IDF LLC | [2017-05-22] | 25.2 M | 3.1 M |
| Filed 2021-01-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund III LP | [2017-02-15] | 255.0 M | 197.8 M |
| Filed 2016-11-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund III Master Non-US LP | [2017-02-15] | 150.0 M | 496.5 M |
| Filed 2016-11-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund II-B Master LP | [2015-03-27] | 126.3 M | 23.0 M |
| Offered $126,265,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund II LP | [2015-03-27] | 419.0 M | 76.6 M |
| Offered $418,965,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Athyrium Opportunities Fund II Master Non-US LP | [2015-03-27] | 675.2 M | 124.8 M |
| Offered $675,250,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 2.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 12 | 2.5 |
| By Discretionary | ||
| Discretionary | 12 | 2.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 12 | 2.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.9 | |
| United States Persons | 0.6 | |
| Total | 12 | 2.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Elin Strong | Executive Officer | 14 | 3 | |
| Jeffrey Ferrell | Executive Officer | 21 | 2 | |
| Andrew Hyman | Executive Officer | 14 | 2 | |
| Jeremy Lack | Executive Officer | 11 | 2 | |
| Paul Wakefield | Executive Officer | 11 | 2 | |
| Courtney Paul | Executive Officer | 8 | 2 | |
| Rashida Adams | Executive Officer | 5 | 2 | |
| Courtney Heizenrader | Executive Officer | 3 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001728001] | |
| 3 | [0001728001] | |
| 4 | [0001728001] | |
| SC 13D | [0001728001] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Athyrium Capital Management LP | Progenity Inc | [2020-07-06] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Biora Therapeutics Inc PROG
Warrant · derivative
|
2021-06-14 | Buy | 8,097,166 | $2.47 | 20,000,000 |
|
Biora Therapeutics Inc PROG
Common Stock
|
2021-06-14 | Buy | 8,097,166 | $2.47 | 20,000,000 |
|
Biora Therapeutics Inc PROG
Common Stock
|
2021-06-01 | Buy | 961,807 | $2.86 | 2,750,768 |
|
Biora Therapeutics Inc PROG
Common Stock
|
2021-06-01 | Buy | 306,308 | $2.86 | 876,041 |
|
Biora Therapeutics Inc PROG
7.25% Convertible Senior Notes due 2025 · derivative
|
2020-12-07 | Buy | 78,500,000 | $78,500,000.00 | 6,162,250,000,000,000 |
|
Biora Therapeutics Inc PROG
Common Stock
|
2020-12-07 | Buy | 4,128,440 | $3.27 | 13,499,999 |
|
Biora Therapeutics Inc PROG
7.25% Convertible Senior Notes due 2025 · derivative
|
2020-12-07 | Buy | 25,000,000 | $25,000,000.00 | 625,000,000,000,000 |
|
Biora Therapeutics Inc PROG
Common Stock
|
2020-06-23 | Buy | 3,333,333 | $15.00 | 49,999,995 |
|
Biora Therapeutics Inc PROG
Unsecured Convertible Promissory Note · derivative
|
2020-06-23 | Conversion | 101,736,263 | ||
|
Biora Therapeutics Inc PROG
Series B Preferred Stock · derivative
|
2020-06-23 | Conversion | |||
|
Biora Therapeutics Inc PROG
Common Stock
|
2020-06-23 | Conversion | 18,319,853 | ||
|
Biora Therapeutics Inc PROG
Common Stock
|
2020-06-23 | Conversion | 1,250,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Bedford Ridge Capital LP
✚
|
NY | 2,606.1 M |
|
LL Funds LLC
✚
|
PA | 2,605.2 M |
|
RGM Capital LLC
✚
|
FL | 2,598.3 M |
|
Aventail Capital Group LP
✚
|
NY | 2,551.7 M |
|
Blackstone Ireland Fund Management Limited
✚
|
2,537.8 M | |
|
Owl Creek Asset Management LP
✚
|
NY | 2,468.3 M |
|
CAS Investment Partners LLC
✚
|
CT | 2,447.2 M |
|
Medalist Partners LP
✚
|
NY | 2,442.9 M |
|
Comvest Advisors LLC
✚
|
FL | 2,429.5 M |
|
Oxford Finance Advisors LLC
✚
|
VA | 2,406.9 M |